{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"Stringent complete remission was defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, 5% or fewer plasma cells in bone marrow, normal free light chain ratio, and the absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","groups":[{"description":"Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT","id":"OG000","title":"Gemcitabine/Busulfan/Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only 65 participants had measurable disease at the time of ASCT.","reportingStatus":"POSTED","timeFrame":"100 days post-transplant","title":"Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission","type":"PRIMARY","unitOfMeasure":"Participants"}